TriangleBalstilimab (NCT07516366)
Balstilimab trial for Clear Cell Renal Cell Carcinoma (NCT07516366). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with high-risk clear-cell kidney cancer that has not spread to distant organs and can be removed surgically. Prior systemic kidney-cancer treatment is excluded; removable local recurrence can qualify.
The idea: give intravenous botensilimab and balstilimab before kidney surgery. They block CTLA-4 and PD-1 immune brakes, aiming to help T cells attack cancer. Surgery is planned 12–16 weeks after treatment starts.
This phase 2 study plans 16 patients. The National Cancer Institute sponsors it, with five recruiting US sites. Researchers assess side effects and whether surgery occurs on time.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.